Flt3 ligand does not differentiate between Parkinsonian disorders.
Research output: Contribution to journal › Article
Differential diagnosis of parkinsonian disorders is challenging because of overlapping symptoms, especially during early stages of disease. No validated biomarkers are available for early and accurate diagnosis of multiple system atrophy and other parkinsonian disorders. It has been reported that flt3 ligand levels in cerebrospinal fluid could clearly differentiate patients with Parkinson's disease from patients with multiple system atrophy, with 99% sensitivity and 95% specificity.
|Research areas and keywords||
Subject classification (UKÄ) – MANDATORY
|Publication status||Published - 2014|